Our News

We are pleased to announce that Hematologics has recently completed the standardization of our flow-based diagnostic and monitoring myeloid panels. The updated panel was implemented on January 8, 2024. The modifications are slight, but they serve to improve the link between the diagnostic and monitoring data and the assessment of phenotypic shifts. The improved assay also provides a more efficient assessment of the flow data with improved resolution of B-cell progenitors, basophils, and dendritic cells. Please feel free to contact your Clinical Outreach representative or contact the laboratory directly via phone or email with any questions or for additional information.

Hematologics Staff 2023 Publications: Click Here

Gemtuzumab Ozogamcin added to conventional chemo improved outcomes for KMT2A-c-AML; consolidation with hematopoietic stem cell transplant may further enhance outcomes.

Lambo et al. use single cell sequencing analyses of clinical trial samples to identify molecular changes associated with relapsed pediatric acute myeloid leukemia. Compared to tumors at diagnosis, they find that relapsed tumors are enriched in primitive cells and typically lose myeloid transcriptional programs while adopting the transcriptional programs of other cell lineages.

HematoLogics Publication showing the integrated analysis of genotype and phenotype revealing the clonal evolution and cytogenetically driven disruption of myeloid cell maturation and myelodysplastic syndromes.

HematoLogics Publication outlining the instrumental use of FACS FISH for the detection of BCR::ABL-1 positive T-cell lymphoblastic leukemia arising in early lymphoid progenitor cells and possible treatment implications.

CD33 SNP sequencing analysis can predict whether a patient responds to Mylotarg therapy.

HematoLogics is the recognized leader for Measurable Residual Disease testing for Acute Leukemia.

Our Expertise

Residual Disease

Small numbers of residual malignant cells are associated with clinical relapse at a later date. HematoLogics is the leader in residual disease testing by flow cytometry using a Difference from normal approach. We also offer a comprehensive menu of quantitative PCR assays for translocations, flow cytometric cell sorting and molecular profiling by DNA analysis.

Cytopenias  /MDS

HematoLogics has found that 30% of all cytopenias are associated with abnormal myeloid cells. With our unique  Flow Cytometric analysis, we use  ∆N: (Difference from Normal) Flow Cytometry and assign an MDS Flow score that is associated with Myelodysplastic syndromes. We also offer aCGH/SNP microarray (LOH), FISH panels, cytogenetic karyotypes,  comprehensive DNA mutation panels, and Next Generation Sequencing.

Plasma Cells

HematoLogics combines plasma cell enrichment and plasma cell sorting for FISH and aCGH/SNP microarray analysis for the diagnosis, prognosis, and monitoring of plasma cell neoplasms. For patients with concurrent monoclonal B-cell and plasma cell populations, we offer PCR IGH monoclonality profiling and MYD88 on the sorted populations to establish the diagnosis.


HematoLogics has extensive experience analyzing biopsies from patients on clinical trials, including those treated with novel therapies. Please contact us to find out more about how we can help clinical trial monitoring or assessment of new drug targets for the treatment of myeloid or lymphoid neoplasms.

Who We Are

HematoLogics has assembled an in-house group of experts in each diagnostic field so that all testing is performed at HematoLogics and not sent out to other specialty labs.

This speeds up analysis and permits rapid response to unexpected findings due to communication between directors on every case.

What We Do

HematoLogics provides immunophenotyping, cytogenetics, fluorescence in situ hybridization, molecular analysis studies, next-generation sequencing, and our own state-of-the-art ∆N: (Difference from Normal) Flow Cytometry

Send us a sample, and we will provide full interpretive reports.

Come Visit HematoLogics